Member Info for davidpqz

For those of you who are not already aware of it mining.com is a great resource. Of particular interest is this recent article: https://www.mining.com/cop26-will-be-a-colossal-mining-cop-out/

Yes Stocko rates ATYM the most highly among the mining stocks. Will follow up your comments with interest.

When is the solar coming online; will it be adequate to requirements?

Yep but the energy crisis is very recent.

Prior to this recent rise in the copper price ATYM was undervalued and my calculations show fair value of at least £6. The sp surge today is being driven by the copper price but what is driving that? Over the last year the price of copper has been much higher than in previous years due to demand and ATYM with its high AISC is a geared play on that. Now however we are probably seeing the copper price rising due to very high power costs i.e. it's coming from the supply side. This implies that the AISC is rising and profits, probably not at all. Sorry to rain on your parade :-)

Obviously I'm in the wrong place for intelligent replies.

Stick2Facts has asked a pertinent question which may have been overlooked as it was in a frivolous thread. I'll repeat it, "Can anyone advise on the effects if any of the astronomical rise in the price of energy against the output cost/tonne copper - seems to be having a drastic effect over here."
As copper is produced by electrolysis (by the next link in the supply chain up from ATYM ) how might we be affected? Is the recent rise in the price of copper due to increased energy costs rather than increased demand?

I think your question is answered in the Proactive interview.

In the Q&A session this morning they said in effect, that they could have guided higher but didn't due to current conditions which I took to mean the possibility of supply probs. I also sold but managed to get back in picking up some extra shares !

I stopped listening to anything Winnifroth has to say a very, very long time ago.

I agree that there is a great future potential for SNG001 however I there are likely to be a few shocks to the share price before we get there. Firstly they have burned through half of their cash pile in H1 and if they continue at this rate will need to issue more shares. Secondly Merck is only the first to be coming to market with a covid pill and these announcements will hit the share price. On the positive side SNG001 is a treatment for any viral inflammatory respiratory condition and there still remains a huge market for it outside of covid.

Apologies. According to Google Finance it's a near 27% rise. Extraordinary!

It's odd that there's no 'price monitoring extension' RNS after a near 26% rise.

Wed 03:05

Posts: 241

Price: 92.00

No Opinion
Bagrak posted:
"According to a report from IHS Markit. The report projects that semiconductor shortages across the automotive sector will extend into the first quarter of 2022, and possibly into the second."
Given that the markets are generally said to be looking six months ahead, maybe we haven't got too long to wait?

I think the share price will rise as the reduced rents and increased online activity from covid feed through. However, longer term this is not a share I want to hold because I have no faith in the management .

For what it's worth, Stocko shows them as having £75m cash, no debt and an annual cash burn that only once got above £10m in recent years. However, I'm not up to date with the £30m issue. And right now it's late and possibly my judgement has been affected by other things!

Only one in four drugs pass through the (usually) three stages of clinical trials. Most of this seems to be preclinical and I still haven't a clue what "cocrystal" means. I've listened to a lot of words but I still do not understand what is on offer here. Please be very, very careful.

Kiwi 1% of 10% is 0.1%. Someone took your badly worded message to mean that Polygon had recently spent £35m on shares not £3.5 m. Go back to school, clever dick.

Some simple arithmetic (no charts needed).
Shares in issue 147m.
Predicted net profit for 2022 £461m
Divide the two and you get earnings per share of 314p.
Assume an undemanding pe of 8 and multiply the two together to get the corresponding share price = £25.12.
Scary innit?
BUT this is all predicated on successful phase 3 trials and regulatory approval.
There, don't you feel better now. That's better than lines on charts.

Schmarts chartz. Random lines drawn on a chart are baloney. Positive Phase 3 clinical trial results are an entirely different matter.